Search results
Showing 1321 to 1335 of 1559 results for do not do recommendations
Infracoccygeal sacropexy using mesh to repair uterine prolapse (HTG443)
Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.
This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.
View quality statements for QS145Show all sections
Sections for QS145
- Quality statements
- Quality statement 1: Follow-up invitations
- Quality statement 2: Offering outstanding vaccinations
- Quality statement 3: Recording vaccinations
- Quality statement 4: Checking immunisation status at specific educational stages
- Quality statement 5: Checking immunisation status of young offenders and offering outstanding vaccinations
- Update information
- About this quality standard
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
DOAC Dipstick for detecting direct oral anticoagulants (MIB248)
NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.